Roberto Giugliani, MD, PhD, on Advantages of Gene Therapy in MPS Type 2

Video

The professor of genetics at Federal University of Rio Grande do Sul discussed how RGX-121 has the potential to change the treatment landscape of MPSII.

“Patients with the severe form of MPS have progressive cognitive decline. Along the first few years of life, they start to slow down in the neurological development. They do not progress. And at the end, they start to some regress in this development. This is something that occurs in about 75% of patients with MPS that have this severe form. So, there is a need for the majority of patients with MPS to have a therapy to address the central nervous system deterioration.”

The gene therapy RGX-121 (REGENXBIO) was well-tolerated with promising efficacy in treating mucopolysaccharidosis type 2 (MPS II; Hunter syndrome), according to updated data from the phase 1/2/3 CAMPSIITE trial (NCT03566043).

These data were presented at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2022 Annual Symposium, in Freiburg, Germany, taking place August 30 – September 2, 2022, by Roberto Giugliani, MD, PhD, professor, genetics, Federal University of Rio Grande do Sul and chief, medical genetics service,Clinic Hospital of Porto Alegre, Rio Grande do Sul, Brazil.

CGTLive spoke with Giugliani to learn more about the potential advantages of RGX-121 gene therapy in MPSII. He discussed unmet needs in this patient population.

REFERENCE
Giugliani R. RGX-121 gene therapy for the treatment of severe mucopolysaccharidosis type II (MPS II): Interim analysis of data from a phase 1/2 study. Presented at: SSIEM 2022 Annual Symposium, Freiburg, Germany, August 30 – September 2, 2022.
Recent Videos
Manali Kamdar, MD, on Liso-Cel's Ongoing Benefit in the Treatment Lanscape for LBCL
Steve Kanner, PhD, the chief scientific officer of Caribou Biosciences
David Dimmock, MBBS, on AI-Guided ASO Development for Ultra-Rare Diseases
Manali Kamdar, MD, on The Importance of Bringing Liso-Cel to Earlier Lines of Lymphoma Treatment
Subhash Tripathi, PhD, on Generating In Vivo CARs With A2-CAR-CISC EngTreg Cells
Luke Roberts, MBBS, PhD, on Challenges in Developing Gene Therapy for Heart Failure
Steve Kanner, PhD, the chief scientific officer of Caribou Biosciences
Paul Y. Song, MD, the chairman and chief executive officer of NKGen
Lisa Nieland on Slowing Tumor Growth in Glioblastoma With Novel AAV Therapy
Manali Kamdar, MD, on Acclimating to Routine CAR T Practice in the Field
© 2024 MJH Life Sciences

All rights reserved.